Skip to content

Clinical pathway study of drug gene-directed clopidogrel individualized and precise medication

Clinical pathway study of drug gene-directed clopidogrel individualized and precise medication

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015597
Enrollment
Unknown
Registered
2018-04-11
Start date
2018-05-01
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndromes

Interventions

Case series:clopidogrel

Sponsors

Yijishan Hospital of Wannan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) aged 20~70 years old; (2) have the indications of cardiovascular and cerebrovascular interventional therapy; (3) have the indications of double anti-platelet therapy with aspirin and clopidogrel, of which the patients with percutaneous coronary intervention persist in taking medicine for 1 years, and the patients with cerebrovascular diseases adhere to take the drug for 6 months; (4) patients are fully informed of the whole process of clinical diagnosis and treatment and potential adverse events. The various conditions that may occur in the clinical diagnosis and treatment, which are not related to this research and sign the informed consent; (5) the patient's hospitalization time is not less than 5 days after postoperation; (6) The compliance of patients is higher, which can lead to the completion of this project and follow up.

Exclusion criteria

Exclusion criteria: (1) patients with aspirin or clopidogrel anaphylaxis or intolerance, as well as patients with aspirin resistance detected by thromboelastography (TEG); (2) patients with hematological diseases, hemorrhagic diseases or bleeding; (3) patients with severe liver and kidney dysfunction; (4) combined with tumors, severe immune system diseases, or other end-stage diseases; (5) patients with a history of apoplexy or visceral hemorrhagic disease in half a year; (6) patients with severe heart failure (NYHA IV) or severe anemia (hemoglobin 180mmHg or diastolic pressure > 120mmHg); (8) there is a taboo antiplatelet therapy or a recent surgical procedure; (9) women in pregnancy and lactation; (10) blood donation or as a volunteer of blood sampling in the last 3 months;

Design outcomes

Primary

MeasureTime frame
Inhibition of platelet aggregation;Concentration of clopidogrel acid;adverse events;

Countries

China

Contacts

Public ContactLuan Jiajie

Yijishan Hospital of Wannan Medical College

luanjiajie757@163.com+86 15855965132

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026